nmpЖурнал им. Н.В. Склифосовского «Неотложная медицинская помощь»Russian Sklifosovsky Journal "Emergency Medical Care"2223-90222541-8017“N.V. Sklifosovsky Research Institute for Emergency Medicine”10.23934/2223-9022-2019-8-1-68-73nmp-589Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREАнемия у больных с хронической сердечной недостаточностью: современное состояние проблемыAnemia in Patients with Heart Failure: Current State of the Problemhttps://orcid.org/0000-0002-8505-1848ГиляревскийС. Р.GilyarevskyS. R.

Гиляревский Сергей Руджерович – доктор медицинских наук, профессор кафедры клинической фармакологии и терапии РМАНПО

125993 Москва, ул. Баррикадная, д. 2/1

Sergey R. Gilyarevsky – Dr. Med. Sci., Professor of the Department of Clinical Pharmacology and Therapy of RMACPE

2/1 Barrikadnaya St., Moscow 125993

sgilarevsky@gmail.comhttps://orcid.org/0000-0002-9865-4998ГолшмидМ. В.GolshmidM. V.

Голшмид Мария Владимировна – кандидат медицинских наук, доцент кафедры клинической фармакологии и терапии РМАНПО

125993 Москва, ул. Баррикадная, д. 2/1

Maria V. Golshmid  – Cand. Med. Sci., Associate Professor of the Department of Clinical Pharmacology and Therapy of RMACPE

2/1 Barrikadnaya St., Moscow 125993

https://orcid.org/0000-0001-9458-7305КузьминаИ. М.KuzminaI. M.

Кузьмина Ирина Михайловна – кандидат медицинских наук, ведущий научный сотрудник отделения неотложной кардиологии

129090 Москва, Б. Сухаревская пл., д. 3

Irina M. Kuzmina  – Cand. Med. Sci., Leading Researcher, Department of Emergency Cardiology

3 Bolshaya Sukharevskaya Square, Moscow 129090

https://orcid.org/0000-0003-3102-1958БенделианиН. Г.BendelianiN. G.

Бенделиани Нана Георгиевна – доктор медицинских наук, старший научный сотрудник научно-консультативного отделения института коронарной и сосудистой хирургии (ИКиСХ) консультативно-диагностического центра (КДЦ) Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии имени А.Н. Бакулева» Министерство здравоохранения РФФГБУ «НМИЦССХ им. А.Н.Бакулева» Минздрава России

121552 Москва, Рублевское ш., д. 135

Nana G. Bendeliani  – Dr. Med. Sci., Senior Researcher of Scientifc Advisory Department of the Institute of Coronary and Vascular Surgery (ICVS)Consultative and Diagnostic Center (CDC), A.N. Bakulev NMRCCVS of the Ministry of Health of Russian Federation

8 Leninsky Ave., Moscow 117931

ГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationRussian FederationГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. Москвы»РоссияN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentRussian Federation«Национальный медицинский исследовательский центр сердечно-сосудистой хирургии имени А.Н. Бакулева»РоссияA.N. Bakulev National Medical Research Center of Cardiovascular SurgeryRussian Federation201923042019816873Copyright © Гиляревский С.Р., Голшмид М.В., Кузьмина И.М., Бенделиани Н.Г., 20192019Гиляревский С.Р., Голшмид М.В., Кузьмина И.М., Бенделиани Н.Г.Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M., Bendeliani N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jnmp.ru/jour/article/view/589

В статье рассмотрена современная тактика лечения больных с хронической сердечной недостаточностью и сопутствующей анемией. Обсуждаются результаты наиболее важных рандомизированных клинических исследований, которые стали основанием для разработки подходов к лечению анемии в таких случаях. Уделяется внимание и нерешенным проблемам лечения анемии у больных с сердечной недостаточностью (СН). Приводятся данные о внутривенном введении препаратов железа как наиболее эффективном подходе к лечению анемии у больных с сердечной недостаточностью при наличии дефицита железа. Рассматриваются основные положения современных клинических рекомендаций по тактике ведения больных с СН и анемией.

The article reports the modern tactics of treating patients with chronic heart failure and concomitant anemia. The results of the most important randomized clinical trials that are the basis for developing approaches to the treatment of anemia in such cases are discussed. Attention is also paid to unresolved problems in the treatment of anemia in patients with heart failure. The data on the intravenous administration of iron preparations as the most effective approach to the treatment of anemia in patients with heart failure in the presence of iron defciency are given. The main provisions of modern clinical guidelines on the management of patients with heart failure and anemia are considered.

хроническая сердечная недостаточностьанемияпрепараты железаchronic heart failureanemiairon preparationsReferencesGrote Beverborg N., van Veldhuisen D.J., van der Meer P. Anemia in Heart Failure. Still Relevant? ACC Heart Fail. 2018; 6(3): 201–208. PMID: 29128254. DOI: 10.1016/j.jchf.2017.08.023.Grote Beverborg N., van Veldhuisen D.J., van der Meer P. Anemia in Heart Failure. Still Relevant? ACC Heart Fail. 2018; 6(3): 201–208. PMID: 29128254. DOI: 10.1016/j.jchf.2017.08.023.van Veldhuisen D.J., Anker S.D., Ponikowski P., Macdougall I.C. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat. Rev. Cardiol. 2011; 8(9): 485-493. PMID: 21629210. DOI: 10.1038/nrcardio.2011.77.van Veldhuisen D.J., Anker S.D., Ponikowski P., Macdougall I.C. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011; 8(9): 485–493. PMID: 21629210. DOI: 10.1038/nrcardio.2011.77.Adlbrecht C., Kommata S., Hülsmann M., et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur. Heart J. 2008; 29(19): 2343–2350. PMID: 18701467. DOI: 10.1093/eurheartj/ehn359.Adlbrecht C., Kommata S., Hülsmann M., et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J. 2008; 29(19): 2343–2350. PMID: 18701467. DOI: 10.1093/eurheartj/ehn359.Grote Beverborg N., Verweij N., Klip I.T., et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One. 2015; 10(4): e0125215. PMID: 25915923. DOI: 10.1371/journal.pone.0125215.Grote Beverborg N., Verweij N., Klip I.T., et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One. 2015; 10(4): e0125215. PMID: 25915923. DOI: 10.1371/journal.pone.0125215.Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients. a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2008; 52(10): 818–827. PMID: 18755344. DOI: 10.1016/j.jacc.2008.04.061.Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients. a systematic review and meta-analysis. J Am Coll Cardiol. 2008; 52(10): 818–827. PMID: 18755344. DOI: 10.1016/j.jacc.2008.04.061.Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol. 2008; 51(5): 569–576. PMID: 18237687. DOI: 10.1016/j.jacc.2007.07.094.Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008; 51(5): 569–576. PMID: 18237687. DOI: 10.1016/j.jacc.2007.07.094.Waldum B., Westheim A.S., Sandvik L., et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J. Am. Coll. Cardiol. 2012; 59(4): 371–378. MID: 22261159. DOI: 10.1016/j.jacc.2011.10.864.Waldum B., Westheim A.S., Sandvik L., et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol. 2012; 59(4): 371–378. PMID: 22261159. DOI: 10.1016/j.jacc.2011.10.864.Klip I.T., Comin-Colet J., Voors A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am. Heart J. 2013; 165(4): 575–582.e3. PMID: 23537975. DOI: 10.1016/j.ahj.2013.01.017.Klip I.T., Comin-Colet J., Voors A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013; 165(4): 575–582.e3. PMID: 23537975. DOI: 10.1016/j.ahj.2013.01.017.Okonko D.O., Mandal A.K., Missouris C.G., Poole- Wilson P.A. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 2011; 58(12): 1241–1251. PMID: 21903058. DOI: 10.1016/j.jacc.2011.04.040.Okonko D.O., Mandal A.K., Missouris C.G., Poole-Wilson P.A. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011; 58(12): 1241–1251. PMID: 21903058. DOI: 10.1016/j.jacc.2011.04.040.Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 2006; 48(12): 2485–2489. PMID: 17174186. DOI: 10.1016/j.jacc.2006.08.034.Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006; 48(12): 2485–2489. PMID: 17174186. DOI: 10.1016/j.jacc.2006.08.034.van der Meer P., Lok D.J., Januzzi J.L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur. Heart J. 2008; 29(12): 1510–1515. PMID: 18495690. DOI: 10.1093/eurheartj/ehn205.van der Meer P., Lok D.J., Januzzi J.L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J. 2008; 29(12): 1510–1515. PMID: 18495690. DOI: 10.1093/eurheartj/ehn205.Westenbrink B.D., Visser F.W., Voors A.A., et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur. Heart J. 2007; 28(2): 166–171. PMID: 17158825. DOI: 10.1093/eurheartj/ehl419.Westenbrink B.D., Visser F.W., Voors A.A., et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2007; 28(2): 166–171. PMID: 17158825. DOI: 10.1093/eurheartj/ehl419.Westenbrink B.D., Voors A.A., De Boer R.A., et al. Bone marrow dysfunction in chronic heart failure patients. Eur. J. Heart Fail. 2010; 12(7): 676–684. PMID: 20427614. DOI: 10.1093/eurjhf/hfq061.Westenbrink B.D., Voors A.A., De Boer R.A., et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail. 2010; 12(7): 676–684. PMID: 20427614. DOI: 10.1093/eurjhf/hfq061.van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 2004; 44(1): 63–67. PMID: 15234408. DOI: 10.1016/j.jacc.2004.03.052.van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004; 44(1): 63–67. PMID: 15234408. DOI: 10.1016/j.jacc.2004.03.052.van der Meer P., Lipsic E., Westenbrink B.D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurence of anemia in heart failure. Circulation. 2005; 112(12): 1743– 1747. PMID: 16172283. DOI: 10.1161/CIRCULATIONAHA.105.549121.van der Meer P., Lipsic E., Westenbrink B.D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurence of anemia in heart failure. Circulation. 2005; 112(12): 1743– 1747. PMID: 16172283. DOI: 10.1161/CIRCULATIONAHA.105.549121.Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2005; 45(3): 391–399. PMID: 15680718. DOI: 10.1016/j.jacc.2004.10.038.Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005; 45(3): 391–399. PMID: 15680718. DOI: 10.1016/j.jacc.2004.10.038.Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 2006; 27(12): 1440–1446. PMID: 16717081. DOI: 10.1093/eurheartj/ehl012.Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006; 27(12): 1440–1446. PMID: 16717081. DOI: 10.1093/eurheartj/ehl012.Weiskopf R.B., Viele M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998; 279(3): 217–221. PMID: 9438742.Weiskopf R.B., Viele M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998; 279(3): 217—221. PMID: 9438742.Ebner N., Jankowska E.A., Ponikowski P., et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating comorbidities aggravating heart failure. Int. J. Cardiol. 2016; 205: 6–12. PMID: 26705670. DOI: 10.1016/j.ijcard.2015.11.178.Ebner N., Jankowska E.A., Ponikowski P., et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating comorbidities aggravating heart failure. Int J Cardiol. 2016; 205: 6–12. PMID: 26705670. DOI: 10.1016/j.ijcard.2015.11.178.Klip I.T., Jankowska E.A., Enjuanes C., et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur. J. Heart Fail. 2014; 16(6): 655–662. PMID: 24644024. DOI: 10.1002/ejhf.84.Klip I.T., Jankowska E.A., Enjuanes C., et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur J Heart Fail. 2014; 16(6): 655–662. PMID: 24644024. DOI: 10.1002/ejhf.84.Garty M., Cohen E., Zuchenko A., et al. Blood transfusion for acute decompensated heart failure–friend or foe? Am. Heart J. 2009; 158(4): 653–658. PMID: 19781427. DOI: 10.1016/j.ahj.2009.08.001.Garty M., Cohen E., Zuchenko A., et al. Blood transfusion for acute decompensated heart failure — friend or foe? Am Heart J. 2009; 158(4): 653–658. PMID: 19781427. DOI: 10.1016/j.ahj.2009.08.001.Kao D.P., Kreso E., Fonarow G.C., Krantz M.J. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000–2006). Am. J. Cardiol. 2011; 107(1): 69–73. PMID: 21146689. DOI: 10.1016/j.amjcard.2010.08.046.Kao D.P., Kreso E., Fonarow G.C., Krantz M.J. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000–2006). Am J Cardiol. 2011; 107(1): 69–73. PMID: 21146689. DOI: 10.1016/j.amjcard.2010.08.046.Qaseem A., Humphrey L.L., Fitterman N., et al. Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2013; 159(11): 770– 779. PMID: 24297193. DOI: 10.7326/0003-4819-159-11-201312030-00009.Qaseem A., Humphrey L.L., Fitterman N., et al. Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159(11): 770– 779. PMID: 24297193. DOI: 10.7326/0003-4819-159-11-201312030-00009.Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N. Engl. J. Med. 2013; 368(13): 1210–1219. PMID: 23473338. DOI: 10.1056/NEJMoa1214865.Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013; 368(13): 1210–1219. PMID: 23473338. DOI: 10.1056/NEJMoa1214865.Bello N.A., Lewis E.F., Desai A.S., et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur. J. Heart Fail. 2015; 17(11): 1201–1207. PMID: 26423928. DOI: 10.1002/ejhf.412.Bello N.A., Lewis E.F., Desai A.S., et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail. 2015; 17(11): 1201–1207. PMID: 26423928. DOI: 10.1002/ejhf.412.Lewis G.D., Semigran M.J., Givertz M.M., et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ. Heart Fail. 2016; 9(5): pii: e000345. PMID: 27140203. DOI: 10.1161/CIRCHEARTFAILURE.115.000345.Lewis G.D., Semigran M.J., Givertz M.M., et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail. 2016; 9(5): pii: e000345. PMID: 27140203. DOI: 10.1161/CIRCHEARTFAILURE.115.000345.Toblli J.E., Lombrana A., Duarte P., Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 2007; 50(17): 1657–1665. PMID: 17950147. DOI: 10.1016/j.jacc.2007.07.029.Toblli J.E., Lombraña A., Duarte P., Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007; 50(17): 1657–1665. PMID: 17950147. DOI: 10.1016/j.jacc.2007.07.029.Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 2008; 51(2): 103–112. PMID: 18191732. DOI: 10.1016/j.jacc.2007.09.036.Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008; 51(2): 103–112. PMID: 18191732. DOI: 10.1016/j.jacc.2007.09.036.Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009; 361(25): 2436–2448. PMID: 19920054. DOI: 10.1056/NEJMoa0908355.Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436–2448. PMID: 19920054. DOI: 10.1056/NEJMoa0908355.Ponikowski P., Van Veldhuisen D.J., Comin-Colet J., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 2015; 36(11): 657–668. PMID: 25176939. DOI: 10.1093/eurheartj/ehu385.Ponikowski P., Van Veldhuisen D.J., Comin-Colet J., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015; 36(11): 657–668. PMID: 25176939. DOI: 10.1093/eurheartj/ehu385.van Veldhuisen D.J., Ponikowski P., van der Meer P., et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017; 136(15): 1374–1383. PMID: 28701470. DOI: 10.1161/CIRCULATIONAHA.117.027497.van Veldhuisen D.J., Ponikowski P., van der Meer P., et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017; 136(15): 1374–1383. PMID: 28701470. DOI: 10.1161/CIRCULATIONAHA.117.027497.Grote Beverborg N., van der Meer P., Klip T., Voors A. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients Circulation Heart Fail. 2018; 11(2): e004519. DOI: 10.1161/CIRCHEARTFAILURE.117.004519.Grote Beverborg N., van der Meer P., Klip T., Voors A. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circulation Heart Fail. 2018; 11(2): e004519. PMID: 29382661. DOI: 10.1161/CIRCHEARTFAILURE.117.004519.Anker S.D., Kirwan B.A., van Veldhuisen D.J., et al. Effects of ferric carboxymaltose on hospital- isations and mortality rates in irondeficient heart failure patients: an individual patient data metaanalysis. Eur. J. Heart Fail. 2018; 20(1): 125–133. PMID: 28436136. DOI: 10.1002/ejhf.823.Anker S.D., Kirwan B.A., van Veldhuisen D.J., et al. Effects of ferric carboxymaltose on hospital- isations and mortality rates in irondeficient heart failure patients: an individual patient data metaanalysis. Eur J Heart Fail. 2018; 20(1): 125–133. PMID: 28436136. DOI: 10.1002/ejhf.823.Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37(2): 2129–2200. PMID: 27206819. DOI: 10.1093/eurheartj/ehw128.Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(2): 2129–2200. PMID: 27206819. DOI: 10.1093/eurheartj/ehw128.Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 62(16): e147–239. PMID: 23747642. DOI: 10.1016/j.jacc.2013.05.019.Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16): e147–239. PMID: 23747642. DOI: 10.1016/j.jacc.2013.05.019.

The authors declare that there are no conflicts of interest present.